Background
==========

Chronic heart failure (HF) is a major cause of morbidity and mortality particularly in the elderly and a growing problem in most affluent countries given the expansion of aging populations ([@b16]; [@b14]). In Italy, one of the countries in the world with the highest proportion of persons above 65 years of age ([@b27]), HF creates a significant burden on healthcare budgets ([@b25]). While advances in the management of HF in the past several decades have significantly decreased the mortality and morbidity associated with this condition, hospitalization rates due to HF have remained on an upward trend ([@b11]; [@b10]). This may be due to a rise in both chronic HF incidence and survival.

Cost-effective HF disease management and prevention are programs of equal importance in the drive to successfully combat the burden of the widespread disease of HF in Italy. The aim must begin with the reduction of HF hospitalization and it can therefore be expected that re-hospitalization rates are factors that will be increasingly scrutinized in the selection of HF treatments by healthcare providers in justifying the cost of treatment. The current paper describes the cost-effectiveness of candesartan cilexetil for the treatment of HF in Italy.

Results of the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) program ([@b26]; [@b8]; [@b17], [@b18]; [@b22]; [@b31]; [@b30]) suggest that candesartan reduces morbidity and mortality in patientswith HF and LV ejection fraction (LVEF) ≤40%, as well as those with LVEF \>40%. Thus, when administered as an alternative to an angiotensin-converting enzyme (ACE) inhibitor, or as an add-on to standard therapy including an ACE inhibitor and/or beta blockers, candesartan has been shown to provide cardiovascular benefits in symptomatic HF including the decrease in the risk of hospital admission for worsening HF and deaths due to cardiovascular causes in HF. These outcomes have been further translated into economic benefits based on the analysis of cost-consequence and cost-effectiveness of the resource use data collected prospectively alongside the CHARM study ([@b23]). The focus of the current paper is on the cost effectiveness of candesartan in HF from the perspective of the National Health Service (SSN Servizio Sanitario Nazionale) in Italy.

Methods
=======

Study design
------------

A pre-specified economic evaluation was conducted on resource utilization collected alongside the CHARM program. Methods employed in the current research complied with the published guidelines for the conduct of economic evaluations in Italy ([@b1]). In addition, given the multinational scope of economic evaluations (including those previously published ([@b19]) conducted alongside the CHARM program, and the inherent methodological challenges that exist for meeting the important objectives of generalizability, transparency, and statistical power, the research methods employed were also developed in respect to the consensus frameworks that are currently being developed in the literature to address these difficulties ([@b23]).

Within the CHARM program itself, patients with NYHA Class II-IV HF recruited from 26 countries were enrolled into one of three trials: CHARM-Alternative (patients with LVEF 40% or less who were not receiving ACE inhibitors because of previous intolerance) ([@b8]); CHARM-Added (patients with LVEF 40% or less or who were currently receiving ACE inhibitors) ([@b18]); or CHARM-Preserved (patients with LVEF higher than 40%) ([@b31]). Overall, 7601 patients (7599 with data) were randomly assigned candesartan (n = 3803, titrated as tolerated to 32 mg once daily) or matching placebo (n = 3796), and followed up for at least 2 years. The primary outcome of the overall program was all-cause mortality and for the two reduced LVEF trials combined (CHARM Alternative and Added), and for each of the component trials was the composite of cardiovascular death or worsening hospital admission for HF.

Resource utilization data collection
------------------------------------

Data on resource utilization were collected prospectively and only comprised components of direct costs including, cardiovascular drug treatment (eg, digitalis glycosides, diuretics, beta-blockers, calcium channel blockers, other vasodilators, anti-arrhythmic drugs, ACE inhibitors, angiotensin II type 1 receptor blockers \[ARBs\], or other cardiovascular drugs such as lipid-lowering agents and anticoagulants), cardiovascular and non-cardiovascular hospital admission (eg, proportion of patients admitted, number of admissions per patient, number of hospital days per patient) and ward type for cardiovascular admission (eg, intensive/coronary care unit, cardiology, general internal medicine), admissions for cardiovascular reasons (eg, number, duration, ward type), and cardiovascular procedures/operations. For costing non-cardiovascular hospital admissions, it was assumed that 10% of time was spent in intensive care and 90% on the general ward. Indirect costs (work productivity losses) were not considered. The time horizon over which the cost-consequence and incremental cost-effectiveness of candesartan were compared to placebo was equivalent to that observed during the period of the program (ie, no future projections were made).

Estimation of costs
-------------------

### Hospital admissions

For the estimation of costs, two approaches were employed ([@b2]); these included the diagnosis-related group (DRG) costing (with data obtained from Health Ministry, Tariffa Unica Nazionale TUC, 2006) and per diem (hospital bed-day) costing (with data obtained from (Azienda Ospedaliera di Busto Arsizio, Varese -- Administration Dept in a group of Hospitals in Lombardy Region). In this analysis actual recorded days in hospital were multiplied by the daily unit costs of hospital care.

### Drug treatment

The source for drugs costs was Gazzetta Ufficiale n.227, 29.09.2006; these were the standard tariffs for the financial year 2006 and the costs of generic drugs were used where available. Candesartan treatment costs also accounted for the initiation and up-titration of candesartan, and included four extra GP visits and four checks of blood biochemistry ([@b2]).

### Cardiovascular procedures

The DRG costs of cardiovascular procedures and operations were obtained from local government sources (Health Ministry, Tariffa Unica Nazionale TUC, 2006). Where there was a lapse in data given little reliable and comparable public information is available for the per diem costs of cardiovascular procedures, DRG costs were used as proxies in the per diem analysis. All costs were converted to 2006 values using the local price index with the exception of drug prices which are for 2006. Costs are presented in the local currency (Euro) and were discounted at 3% for costs and outcomes (ISTAT 2007; [@b1]). The costs used in this analysis are summarized in [Table 1](#tbl1){ref-type="table"}.

###### 

Unit costs[a](#tf1-1){ref-type="table-fn"} used in the economic analysis of CHARM

  Event                                             DRG cost in Italy
  ------------------------------------------------- -------------------
  **Hospitalizations**                              
   Worsening HF                                     2669.82
   Myocardial infarction                            3356.12
   Unstable angina                                  1882.16
   Stroke                                           
    Hemorrhagic                                     3391.02
    Ischemic/unknown/other                          3391.02
   Transient ischemic attack                        2124.34
   Cardiogenic shock                                2669.82
   Atrial tachyarrhythmia                           2213.55
   Ventricular arrhythmia                           5455.44
   Pulmonary embolism                               3710.82
   Other cardiovascular event                       1765.16
   Cancer (neoplasm)                                2182.41
   Other non-cardiovascular event                   939.69
  **Cardiovascular procedures**                     
   Cardiac catheterizations including angiography   2722.25
   CABG                                             17898.67
   PTCA with stent                                  7878.69
   PTCA without stent                               5455.44
   Implantation of cardioverter defibrillator       23876.00
   Implantation of pacemaker                        9438.59
   Heart transplantation                            61066.70
   Ventricular assist device                        7052.77
   Other cardiac surgery for HF                     19419.16
   Other cardiovascular procedure/operation         9187.76
  **Per diem costs**                                
   Intensive/coronary care unit                     1860.65
   Cardiology ward                                  600
   General medical ward                             200
   Non-cardiovascular admission                     366.07
   Visit general practitioner                       20.66
   Laboratory test -- blood biochemistry            23.81
   Candesartan 4 mg                                 0.83
   Candesartan 8 mg                                 0.69
   Candesartan 16 mg                                0.89
   Candesartan 32 mg                                1.13

All costs shown in Euro (1€ = US\$1.20 and £0.67).

**Abbreviations:** CABG, coronary artery bypass grafting; DRG, diagnosis related group; HF, heart failure; PTCA, percutaneous transluminal coronary intervention.

Economic analysis
-----------------

### Effectiveness parameter employed

The effectiveness parameters employed in the analyses were as follows. For the component trials of the CHARM program the composite of cardiovascular death or hospital admission for worsening HF was employed. The candesartan to placebo hazard ratios for this outcome were as follows: CHARM-Alternative: 0.77 (95% CI 0.67--0.89, p = 0.0004) ([@b8]); CHARM-Added: 0.85 (0.75--0.96, p = 0.011) ([@b18]); CHARM-Preserved: 0.89 (0.77--1.03, p = 0.118) ([@b31]); the overall CHARM program: 0.84 (0.77--0.91, p \< 0.0001) ([@b22]). For the overall CHARM program and for the two reduced LVEF trials combined (CHARM-Alternative and Added) all-cause mortality was the pre-specified primary endpoint ([@b26]). The candesartan to placebo hazard ratio for this outcome in the overall CHARM program was 0.91 (0.83--1.00, p = 0.055) ([@b22]) and in the reduced LVEF trials 0.88 (0.79--0.98, p = 0.018) ([@b30]).

### Economic analyses conducted

The economic analyses were based on the comparison of placebo, ie, standard therapy for HF to candesartan added to standard therapy. Two types of economic analyses were performed: these include a cost-consequence analysis (CCA) for a disaggregated examination of resource costs and health outcomes associated with the alternative interventions; and cost-effectiveness analysis (CEA) in which the alternative interventions are examined in light of total cost per unit of health outcome. Thus CCA was performed for each component trial and for the overall CHARM program using the primary outcome of the component trials as the measure of effectiveness. For this, the annual cost per patient treated to postpone or prevent one patient experiencing a cardiovascular death or hospital admission for worsening HF within the trial was calculated ([@b13]). For CEA, the incremental cost-effectiveness ratios (ICERs), in terms of cost per life year gained (LYG), were estimated for the reduced LVEF trials given that there was a significant increase in survival with candesartan in these two trials combined. CEA was not performed for CHARM-Preserved given that no reduction was observed in that trial for candesartan in cardiovascular or all cause mortality.

### Sensitivity analyses

Univariate sensitivity analyses were conducted by increasing the length of stay for non-cardiovascular admissions by 30% in the candesartan group to model the potential additional cost of possible adverse effects related to candesartan ([@b29]); adding an additional GP visit to account for a possible adverse event or laboratory abnormality; and testing the impact of alternative discount rates for costs and benefits in the range 0% and 8% ([@b1]).

### Statistical methods

Statistical analyses were performed using SAS software (version 8; SAS Institute Inc., Cary, NC, USA). The group mean approach was employed to account for censored data (eg, early dropouts and missing values) ([@b3]) and bootstrapping, a technique which involves re-sampling was implemented as the test for significance.

Results
=======

Clinical outcomes
-----------------

### All-cause hospital admissions

The rates and number of hospital admissions in the overall CHARM program and each component trial ([Table 2](#tbl2){ref-type="table"} and [Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}) show that noteworthy differences between the placebo and treatment groups were obtained for the number of patients hospitalized in CHARM-Overall and CHARM-Alternative. In the CHARM-Overall trial 63.8% of patients in the placebo group were admitted to hospital at least once for any reason, compared with 62.4% in the candesartan group \[odds ratio (OR) 0.94, 95% CI 0.86--1.03, p = 0.20\]. In the CHARM-Alternative trial 63.3% of patients in the placebo group were admitted to hospital at least once for any reason, compared with 60.2% in the candesartan group (odds ratio \[OR\] 0.88, 95% CI 0.71--1.05, p = 0.15).

![Cumulative number of hospital admissions.](vhrm0401-223-01){#fig1}

![Rates of hospital admission for any cause, all cardiovascular (CV) reasons, heart failure (HF) only, and non-cardiovascular reasons (p-values within brackets).](vhrm0401-223-02){#fig2}

###### 

Hospital admissions and patients hospitalized in CHARM

                              CHARM-Alternative                                                           
  --------------------------- ------------------------ ---------------------------- --------------------- -------------
  **All patients**                                                                                        
  Patient-years               2582                     2658                                               
  No. deaths                  296                      265                                                
  No. admissions              1835                     1719                                               
  No. hospl days              16,816                   15,079                                             
  Hosp days/adm               9.16                     8.77                         0.39 (−0.60, 1.38)    0.44
  Adm/patient                 1.81                     1.70                         0.11 (−0.10, 0.32)    0.30
  Hosp days/patient           16.57                    14.89                        1.86 (−1.11, 4.47)    0.24
  Hosp days/patient-year      6.51                     5.67                         0.84 (−0.27, 1.95)    0.13
  **Patients hospitalized**                                                                               
  No. hosp patient            643                      610                          0.88 (0.73, 1.05)     0.15
  Adm/patient                 2.85                     2.82                         0.04 (−0.25, 0.32)    0.80
  Hosp days/patient           26.15                    24.72                        1.43(−2.73, 5.60)     0.50
                                                                                                          
                              **CHARM-Added**                                                             
                                                                                                          
                              **Placebo (n = 1272)**   **Candesartan (n = 1276)**   **Diff (95% CI)**     **p-value**
                                                                                                          
  **All patients**                                                                                        
  Patient-years               3721                     3846                                               
  No. deaths                  412                      377                                                
  No. admissions              2799                     2462                                               
  No. hospl days              24,161                   21,902                                             
  Hosp days/adm               8.63                     8.90                         −0.26 (−0.95, 0.43)   0.45
  Adm/patient                 2.20                     1.93                         0.27 (0.07, 0.47)     0.008
  Hosp days/patient           18.99                    17.16                        1.83 (−0.65, 4.31)    0.15
  Hosp days/patient-year      6.49                     5.7                          0.79 (−0.06, 1.64)    0.070
  **Patients hospitalized**                                                                               
  No. hospit patient          858                      852                          0.97 (0.82, 1.14)     0.71
  Adm/patient                 3.26                     2.89                         0.37 (0.13, 0.62)     0.003
  Hosp days/patient           28.16                    25.71                        2.45 (−0.94, 5.85)    0.16
                                                                                                          
                              **CHARM-Preserved**                                                         
                                                                                                          
                              **Placebo (n = 1509)**   **Candesartan (n = 1514)**   **Diff (95% CI)**     **p-value**
                                                                                                          
  **All patients**                                                                                        
  Patient-years               4387                     4434                                               
  No. deaths                  244                      237                                                
  No. admissions              2548                     2510                                               
  No. hosp days               22,705                   22,942                                             
  Hosp days/adm               8.91                     9.14                         −0.23 (−1.02, 0.56)   0.57
  Adm/patient                 1.69                     1.66                         0.03 (−0.13, 0.20)    0.71
  Hosp days/patient           15.05                    15.15                        −0.11 (−2.20, 2.01)   0.92
  Hosp days/patient-year      5.18                     5.17                         0.01 (−0.73,0.75)     0.98
  **Hospitalized patients**                                                                               
  No. hosp patient            922                      9.12                         0.96 (0.83, 1.12)     0.63
  Adm/patient                 2.76                     2.75                         0.01 (−0.21, 0.23)    0.92
  Hosp days/patient           24.63                    25.16                        −0.53 (−3.71, 2.65)   0.74
                                                                                                          
                              **CHARM-Overall**                                                           
                                                                                                          
                              **Placebo (n = 3796)**   **Candesartan (n = 3803)**   **Diff (95% CI)**     **p-value**
                                                                                                          
  **All patients**                                                                                        
  Patient-years               10,690                   10,938                                             
  No. deaths                  945                      886                                                
  No. admissions              7182                     6691                                               
  No. hosp days               63,681                   59,923                                             
  Hosp days/adm               8.87                     8.96                         −0.09 (−0.55, 0.38)   0.71
  Adm/patient                 1.89                     1.76                         0.13 (0.02, 0.24)     0.018
  Hosp days/patient           16.78                    15.76                        1.02 (−0.38, 2.42)    0.15
  Hosp days/patient-year      5.96                     5.48                         0.48 (−0.02,0.98)     0.056
  **Hospitalized patients**                                                                               
  No.hospitalized patient     2423                     2374                         0.94 (0.86, 1.03)     0.20
  Adm/patient                 2.96                     2.82                         0.15 (0.003, 0.29)    0.045
  Hosp days/patient           26.28                    25.24                        1.04 (−0.99, 3.07)    0.31

Additionally for CHARM-Overall, the number of admissions per patient hospitalized was 2.96 in the placebo group when compared with 2.82 in the candesartan group (p = 0.045). The average length of an individual admission was 8.9 days in the placebo group and 9.0 days in the candesartan group. The average number of days spent in hospital for admitted patients was 26.3 days in the placebo group and 25.2 days in the candesartan group. As a result, treatment with candesartan resulted in fewer hospital admissions (7182 for placebo vs 6691 for candesartan or 1.060 compared with 0.853 admissions per year of follow-up, p = 0.0001) and fewer days in hospital (placebo 63681, candesartan 59923; [Table 2](#tbl2){ref-type="table"}, p = ns). The number of days in hospital per patient-year of follow-up was 6.0 in the placebo group and 5.5 in the candesartan group (p = 0.056).

### Cardiovascular hospital admissions

The frequency of hospital admissions for specific cardiovascular causes ([Table 3](#tbl3){ref-type="table"} and [Figure 2](#fig2){ref-type="fig"}) shows that candesartan reduced both the proportion of patients admitted (−20%) and the number of admissions (−28%) for worsening HF. Atrial tachyarrhythmias also showed a trend toward reduction, while hospital admission for myocardial infarction showed a trend toward reduction in CHARM Added and CHARM Preserved. 'Other' cardiovascular admissions were fewer in the candesartan group in CHARM Alternative and CHARM-Added, and just nominally greater in the candesartan group in CHARM-Preserved. Examination of these miscellaneous admissions did not reveal an excess in any specific category of event.

###### 

Hospital admissions by cause -- number of patients and % of patients admitted

                           CHARM-Alternative   CHARM-Added   CHARM-Preserved   CHARM-Overall                                                                                                                                                                                                                
  ------------------------ ------------------- ------------- ----------------- -------------------------------------------- ------ ------------ ------ ----------------------------------------------- ------ ------------ ------ --------------------------------------------- ------ ------------- ------ --------------------------------------------
  Worsening CHF            608                 291 (28.7)    445               212 (20.9)[†](#tf3-3){ref-type="table-fn"}   836    382 (30.0)   607    323 (25.3)[\*\*](#tf3-2){ref-type="table-fn"}   566    279 (18.5)   402    230 (15.2)[\*](#tf3-1){ref-type="table-fn"}   2010   952 (25.1)    1454   765 (20.1)[†](#tf3-3){ref-type="table-fn"}
  Myocardial infarction    51                  45 (4.4)      55                48 (4.7)                                     64     50 (3.9)     38     36 (2.8)                                        64     61 (4.0)     68     58 (3.8)                                      179    156 (4.1)     161    142 (3.7)
  Unstable angina          109                 74 (7.3)      137               94 (9.3)                                     192    117 (9.2)    145    101 (7.9)                                       235    145 (9.6)    244    154 (10.2)                                    536    336 (8.9)     526    349 (9.1)
  Stroke                   34                  32 (3.2)      35                32 (3.2)                                     38     34 (2.7)     37     34 (2.7)                                        56     52 (3.5)     52     46 (3.0)                                      128    118 (3.1)     124    112 (3.0)
  TIA                      16                  15 (1.5)      16                12 (1.2)                                     10     9 (0.7)      20     19 (1.5)                                        25     21 (1.4)     21     18 (1.2)                                      51     45 (1.2)      57     49 (1.3)
  Hypotension              14                  14 (1.4)      26                20 (2.0)                                     24     22 (1.7)     60     55 (4.3)[†](#tf3-3){ref-type="table-fn"}        15     13 (0.9)     25     23 (1.5)                                      53     49 (1.3)      111    98 (2.6)
  Atrial tachyarrhythmia   44                  34 (3.4)      53                34 (3.4)                                     56     46 (3.6)     61     49 (3.8)                                        123    86 (5.7)     82     59 (3.9)[\*](#tf3-1){ref-type="table-fn"}     223    166 (4.4)     196    142 (3.7)
  Ventricular arrhythmia   55                  39 (3.8)      52                45 (4.4)                                     86     65 (5.1)     68     52 (4.1)                                        16     14 (0.9)     18     17 (1.1)                                      157    118 (3.1)     138    114 (3.0)
  Pulmonary embolism       9                   8 (0.8)       6                 6 (0.6)                                      11     10 (0.8)     6      6 (0.5)                                         9      9 (0.6)      8      8 (0.5)                                       29     27 (0.7)      20     20 (0.53)
  Other CV event           244                 181 (17.8)    225               164 (16.2)                                   416    254 (20.0)   362    249 (19.5)                                      368    247 (16.4)   400    280 (18.5)                                    1028   682 (18.0)    987    693 (18.2)
  CV unknown                                                                                                                                                                                           1      1 (0.0)      1      1 (0.0)                                       1      1 (0.0)       1      1 (0.0)
  Cancer                   55                  35 (3.5)      42                30 (3.0)                                     49     36 (2.8)     83     52 (4.1)                                        84     52 (3.5)     53     40 (2.6)                                      188    123 (3.2)     178    122 (3.21)
  Other non-CV event       596                 334 (32.9)    627               350 (34.6)                                   1017   531 (41.8)   975    525 (41.1)                                      986    546 (36.2)   1136   589 (38.9)                                    2599   1411 (37.2)   2738   1464 (38.5)
  All                      1835                643 (63.4)    1719              610 (60.2)                                   2799   858 (67.5)   2462   852 (66.8)                                      2548   922 (61.1)   2510   912 (60.2)                                    7182   2423 (63.8)   6691   2374 (62.4)

p \< 0.05.

p \< 0.01.

\<0.001 (comparison of proportion of randomized patients).

**Abbreviations:** CV, cardiovascular; TIA, transient ischemic attack.

### Procedures and operations

Other than cardiac catheterizations, the frequency of other cardiovascular procedures ([Table 4](#tbl4){ref-type="table"}), was relatively few and did not differ between treatment groups.

###### 

Number of cardiovascular procedures in CHARM

  Procedure                                                  CHARM-Alternative   CHARM-Added                 CHARM-Preserved   CHARM-Overall                                                                             
  ---------------------------------------------------------- ------------------- --------------------------- ----------------- --------------------------- ---------------- --------------------------- ---------------- -------------------------
  Cardiac catheterization incl. angiography                  160                 139                         228               172                         261              262                         649              573
  CABG                                                       26                  21                          22                39                          42               46                          90               106
  PTCA with stent                                            31                  30                          55                36                          73               78                          159              144
  PTCA without stent                                         11                  10                          19                10                          23               15                          53               35
  Implantation of cardioverter defibrillator                 31                  30                          60                51                          9                9                           100              90
  Implantation of pacemaker                                  50                  49                          75                80                          54               67                          179              196
  Heart transplantation                                      8                   7                           15                17                          0                0                           23               24
  Ventricular assist device                                  6                   6                           3                 1                           0                1                           9                8
  Other cardiac surgery for heart failure                    3                   2                           6                 9                           10               11                          19               22
  Other cardiovascular procedure/operation                   112                 112                         213               188                         196              192                         521              492
  **Total no. CV procedures**                                **438**             **406**                     **696**           **603**                     **668**          **681**                     **1802**         **1690**
  **Total no. patients with CV procedure (% of patients)**   **239 (23.6)**      **218 (21.5) (p = 0.27)**   **349 (27.4)**    **320 (25.1) (p = 0.18)**   **350 (23.2)**   **342 (22.6) (p = 0.69)**   **938 (24.7)**   **880 (23.1) (p = ??)**

**Abbreviations:** CABG, coronary artery bypass grafting; CV, cardiovascular; PTCA, percutaneous transluminal coronary intervention.

Economic outcomes
-----------------

### Costs of adjunctive candesartan treatment

The per diem cost analysis of adding candesartan to conventional treatment ([Table 5](#tbl5){ref-type="table"}) shows that in CHARM-Overall the cost of care in the candesartan group was slightly (1%) less, even taking into account the cost of candesartan. There was a net cost-saving in both CHARM-Alternative and CHARM-Added (5% reduction in cost in both trials). In CHARM-Preserved, there was a net increase in the daily cost of care (6% increase in cost). The results of the DRG analysis ([Table 6](#tbl6){ref-type="table"}) were very similar; there was a small increase observed (2%) in the net daily cost of care with candesartan.

###### 

Daily per patient cost (€) of treatment in CHARM -- per diem analysis

                              CHARM-Alternative                                  CHAR-Added         CHARM-Preserved    CHARM-Overall                                                               
  --------------------------- -------------------------------------------------- ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------
  Hospitalizations            9.33                                               7.99               8.92               7.71               6.95               6.71               8.21               7.37
  Cardiovascular procedures   4.15                                               3.77               4.76               4.43               2.98               3.04               3.88               3.71
  Concomitant medication      2.03                                               1.97               2.62               2.48               1.99               1.87               2.22               2.11
  Study drug                  0.00                                               0.80               0.00               0.79               0.00               0.83               0.00               0.81
  Titration cost              0.00                                               0.18               0.00               0.16               0.00               0.16               0.00               0.17
  **Total**                   **15.51 (0.85)[a](#tf5-1){ref-type="table-fn"}**   **14.71 (0.78)**   **16.30 (0.66)**   **15.56 (0.61)**   **11.93 (0.44)**   **12.61 (0.46)**   **14.31 (0.36)**   **14.16 (0.33)**

standard error within parentheses.

###### 

Daily per patient cost of treatment (€) in CHARM -- DRG analysis

                              CHARM-Alternative                                  CHARM-Added        CHARM-Preserved    CHARM-Overall                                                            
  --------------------------- -------------------------------------------------- ------------------ ------------------ ------------------ ----------------- ----------------- ----------------- -----------------
  Hospitalizations            3.85                                               3.37               3.88               3.18               2.80              2.55              3.43              2.97
  Cardiovascular procedures   4.15                                               3.77               4.76               4.43               2.98              3.04              3.88              3.71
  Concomitant medication      2.03                                               1.97               2.62               2.48               1.99              1.87              2.22              2.11
  Study drug                  0.00                                               0.80               0.00               0.79               0.00              0.83              0.00              0.81
  Titration cost              0.00                                               0.18               0.00               0.16               0.00              0.16              0.00              0.17
  **Total**                   **10.03 (0.50)**[a](#tf6-1){ref-type="table-fn"}   **10.09 (0.44)**   **11.26 (0.44)**   **11.04 (0.39)**   **7.77 (0.25)**   **8.45 (0.25)**   **9.53 (0.23)**   **9.76 (0.20)**

standard error within parentheses.

### CCA

The CCA of the data ([Table 7](#tbl7){ref-type="table"}) shows that adjunctive treatment with candesartan in CHARM-Alternative and CHARM-Added led to clinical benefits and to either cost-savings or a small additional annual cost, depending on the trial. The less certain clinical benefit in CHARM-Preserved was obtained at modest extra cost.

###### 

Cost-consequence analysis of candesartan compared with placebo in the treatment of HF -- clinical benefits and annual per patient saving/cost increase (95% CI)

  Trial               Clinical benefits vs placebo              DRG costs                        Per-diem costs
  ------------------- ----------------------------------------- -------------------------------- --------------------------------
  CHARM-Alternative   CV deaths (−15%) HF admission (−32%)      Net increase (€22 ± 245/year)    Savings (€291 ± 421/year)
  CHARM-Added         CV deaths (−16%) HF admission (−17%)      Savings (€81 ± 214/year)         Savings (€267 ± 328/year)
  CHARM-Preserved     CV deaths (−1%), ns HF admission (−15%)   Net increase (€249 ± 128/year)   Net increase (€249 ± 232/year)
  CHARM-Overall       CV deaths (−12%) HF admission (−21%)      Net increase (€83 ± 111/year)    Savings (€56 ± 179/year)

**Abbreviations:** CV, cardiovascular; DRG, diagnosis related group; HF, heart failure.

### CEA

The CEA of the two reduced LVEF CHARM trials ([Table 8](#tbl8){ref-type="table"}) was conducted using a conservative approach of employing DRG costs only as all scenarios with per diem costs obtained results of cost-savings. Thus, following this approach in terms of the cost per LYG, the incremental cost-effectiveness ratio (ICER) was estimated to range from €713 for CHARM-Alternative to dominant for CHARM-Added and the pooled reduced LVEF data. The results for Italy are consistent with the results in France, Germany, and the UK.

###### 

Cost-effectiveness of candesartan in the CHARM reduced LVEF trials (based on DRG costs)

  CHARM TRIAL LYG (95% CI)   Cost per LYG (95% CI)                                                                                      
  -------------------------- ----------------------- ------------------------------------------ ---------- ---------------------------- ----------------------------
  Alternative                0.078 (0.003--0.15)     €713 (−7736; 431,600)                      Dominant   €3881 (−17,728; 1,105,920)   €2547 (−18 171; 1 059 150)
  Added                      0.061 (−0.002--0.12)    Dominant[a](#tf8-1){ref-type="table-fn"}   Dominant   €1427 (−14,479; −984,755)    Dominant
  Reduced LVEF pooled        0.068 (0.02--0.12)      Dominant                                   Dominant   €2997 (−19,183; 121,500)     €1348 (−16 225; 106 600)

Dominant means a cost per LYG could not be calculated because costs were lower in the candesartan than in the placebo group.

**Abbreviations:** CV, cardiovascular; DRG, diagnosis related group; HF, heart failure; LVEF, left ventricular ejection fraction; LYG, life year gained.

### Sensitivity analyses

The sensitivity analyses ([Table 9](#tbl2){ref-type="table"}) showed that increasing the length of stay for non-cardiovascular admissions by 30% increased the cost per day in the candesartan group by 2%. As a result, candesartan was no longer cost-saving in any comparison. Adding one GP visit for an adverse event or laboratory abnormality which led to a reduction in the dose of, or discontinuation of candesartan resulted in an increase in daily costs by €0.01. As expected the cost per day is sensitive to changes in discount rate 0% and 8%.

###### 

Sensitivity analysis

                                                                           Alternative                   Added                         Preserved                   Overall       
  ------------------------------------------------------------------------ -------------- -------------- -------------- -------------- ------------- ------------- ------------- --------------
  Increasing the length of stay for non-cardiovascular admissions by 30%                                                                                                         
  Total                                                                    10.03 (0.50)   10.30 (0.45)   11.26 (0.44)   11.26 (0.39)   7.77 (0.25)   8.66 (0.25)   9.53 (0.23)   9.97 (0.20)
  Adding one GP visit for an adverse event or laboratory abnormality                                                                                                             
  Total                                                                    10.03 (0.50)   10.10 (0.44)   11.26 (0.44)   11.04 (0.39)   7.77 (0.25)   8.46 (0.25)   9.53 (0.23)   9.77 (0.20)
  Sensitivity analysis 0% costs, 0% benefits                                                                                                                                     
  Total                                                                    10.33 (0.52)   10.37 (0.70)   11.65 (0.46)   11.39 (0.40)   7.98 (0.26)   8.70 (0.26)   9.82 (0.24)   10.05 (0.21)
  Sensitivity analysis 8% costs, 8% benefits                                                                                                                                     
  Total                                                                    9.56 (0.43)    9.64 (0.48)    10.63 (0.41)   10.46 (0.37)   7.42 (0.24)   8.04 (0.24)   9.06 (0.22)   9.28 (0.19)

Discussion
==========

The CHARM program has shown that in treated patients, a substantial reduction in the proportion of patients admitted with worsening HF (and an even more marked reduction in the number of such admissions), without any increase in length of stay, contributed to a reduction in the rate of admission (and hospital bed days) for any reason, though this overall reduction was more modest. This is because the full impact of the reduction in admissions for worsening HF was attenuated by increased survival in the candesartan-treated patients (who, therefore, spent more time at risk of hospital admission for other reasons).

Via economic analysis, it has been shown that the cost-savings accruing from even this modest reduction in the rate of hospital admission for any cause largely offset the cost of candesartan in Italy. According to the method of analysis (per diem compared with DRG), candesartan was, essentially, cost-neutral in the overall-CHARM program (though clinical effectiveness was not proven in one component trial, CHARM Preserved). There was, however, heterogeneity between the component trials in the program. Although candesartan treatment was associated with either a small reduction or increase in the net overall cost of care in CHARM-Alternative and CHARM-Added, depending on the analysis, in CHARM-Preserved (in which candesartan treatment did not reduce the primary endpoint significantly) there was a consistent and modest increase in the net cost of care. There appear to be two reasons for this. Though the proportional reduction in the rate and number of admissions for worsening HF was similar in all three CHARM trials, the absolute number of admissions prevented was smaller, relative to the number of patients treated, in CHARM-Preserved (ie, the rate of admission for worsening HF was lower in CHARM-Preserved, [Figure 2](#fig2){ref-type="fig"}). Consequently, the cost-offset was less in CHARM-Preserved than in the other two trials.

Another possible explanation is the increased number of 'other' cardiovascular admissions in the candesartan group in CHARM-Preserved (a reduction, rather than excess, of these admissions was observed in the other CHARM trials), also observed with cardiovascular procedures in CHARM-Preserved. As no specific pattern could be observed for the excesses in these outcomes, both increases may be viewed as a chance finding. Also noteworthy is the overall net cost of treatment in CHARM-Added (candesartan added to full conventional treatment, including an ACE-inhibitor), which was comparable to the net treatment cost obtained for CHARM-Alternative; and that the essentially cost-neutral outcome of these analyses of CHARM was obtained despite adding the cost of extra clinic visits and biochemical tests to reflect the extra costs related to initiating, up-titrating the dose, and monitoring the effects of candesartan.

Our findings on the cost -- consequences and cost-effectiveness of using candesartan in Italy are consistent with the results observed in the economic evaluations of using candesartan in France, Germany, and the UK ([@b19]). In CE, the ICER was second only to the result obtained for France where candesartan was dominant across both of the reduced LVEF trials as well as their pooled data. Furthermore, although broadly in keeping with economic analyses of other effective treatments for HF ([@b21]; [@b6], [@b7]; [@b2]), it is difficult to directly compare the current and previously published candesartan studies to those. No other placebo-controlled study included such a broad spectrum of patients, had within-trial data for such a long period of follow-up (with the exception of the ACE inhibitor enalapril in the treatment arm of the studies of LV dysfunction in the case of the latter) ([@b3]), or added the drug to such extensive background treatment. Nevertheless, a consistent message from these prior economic analyses and ours is that reduction in hospital admission offsets the cost of treatment. Remarkably, the cost-offset has been sufficient with all treatments examined, to date, to be cost-saving or more or less cost-neutral. This is despite each new drug being used as an additional treatment and against a trend of falling lengths of hospital stay.

The economic results, coupled with the clinical findings of the CHARM program, have clear implications for the management of patients with HF in Italy. Not only does candesartan improve important clinical outcomes in HF but also offers these benefits at little or no additional cost to the health care system; indeed, its use in patients with HF and reduced LV systolic function may lead to an actual reduction in the direct costs of health care. This is an important finding for health-care providers and society more generally, because there is no trade-off between the interest of the individual patient and the greater population served by the health-care system.

As with any analysis of this type there were limitations. By using the full unit cost of candesartan, our analyses have reduced the cost-effectiveness of this treatment for the patient or private insurer who provides a co-payment for the cost of treatment (although this co-payment is exempt for the elderly in Italy). We did not take account of indirect costs, pension payments in those who survived were not taken account, costs related to death out of hospital. We had less detailed and complete information on non-cardiovascular procedures and drugs. However, the main driver of costs is hospital admission and we did have information on these and tried to account for lack of information on the former in our sensitivity analyses.

As with all economic analyses based on clinical trials of limited duration, there is concern that costs may only be postponed and that there may be 'catch-up' over the whole life-time of a patient. We believe that this is unlikely, given the relatively long-duration of follow-up of CHARM (37.7 months) compared with the average life-expectancy of patients with HF. We carried out a cost--consequence analysis of CHARM-Preserved even though the pre-specified primary outcome was not reduced significantly.

In summary, when added to currently recommended treatment, candesartan reduces hospital admissions for worsening HF and increases survival in patients with HF ([@b8]; [@b17], [@b18]; [@b22]; [@b31]), specifically in those with low LVEF ([@b22]; [@b30]) and does this at little or no extra direct cost to the Italian health-care system. Candesartan is, therefore, a clinically and economically attractive adjunctive treatment for HF in Italy, representing significant value to the individual patient as well as to health-care providers.
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